EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

DCIS Progression and the Tumor Microenvironment: Molecular Insights and Prognostic Challenges

Karolina Prajzendanc iD

Cancers · 10.06.2025 · 17 (12) · 1925

DOI: 10.3390/cancers17121925 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 10.06.2025. Verfasst von Karolina Prajzendanc. Beteiligte Einrichtung: Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ductal carcinoma in situ (DCIS) is the most common form of non-invasive breast cancer and a recognized precursor to invasive ductal carcinoma (IDC). Although DCIS itself is confined to the milk duct and not immediately life-threatening, its potential for progression to invasive disease necessitates careful clinical management. The increased detection of DCIS due to advancements in imaging and widespread screening programs has raised critical questions regarding its classification, prognosis, and optimal treatment strategies. While most cases exhibit indolent behavior, others harbor molecular characteristics that drive malignant transformation. A key challenge lies in distinguishing low-risk DCIS, which may never progress, from aggressive cases requiring intervention. Tumor microenvironment dynamics, immune cell infiltration, and molecular alterations, including hormone receptor (HR) status, human epidermal growth factor 2 (HER2) expression, and genetic mutations, play crucial roles in determining disease trajectory. This review explores the biological and molecular mechanisms underlying DCIS progression, with an emphasis on myoepithelial cells, tumor-infiltrating lymphocytes, and microenvironmental factors. By integrating recent findings, this article aims to refine risk stratification approaches and guide future strategies for personalized DCIS management. Improved prognostic biomarkers and targeted therapeutic interventions could help optimize treatment decisions, balancing the need for effective cancer prevention while minimizing overtreatment in low-risk patients.

Schlagwörter

Stichwörter der Autor:innen

DCIS progressionductal carcinoma in situtumor microenvironment

Autor:innen und Institutionen

  • Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 71-252 Szczecin, Poland.

ORCID-Profile: Karolina Prajzendanc

Zitieren

APA

Prajzendanc, K. (2025). DCIS Progression and the Tumor Microenvironment: Molecular Insights and Prognostic Challenges. Cancers, 17(12), 1925. https://doi.org/10.3390/cancers17121925

Vancouver

Prajzendanc K. DCIS Progression and the Tumor Microenvironment: Molecular Insights and Prognostic Challenges. Cancers. 2025;17(12):1925. doi:10.3390/cancers17121925

BibTeX
@article{Prajzendanc2025,
  author = {Prajzendanc, Karolina},
  title = {DCIS Progression and the Tumor Microenvironment: Molecular Insights and Prognostic Challenges},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {12},
  pages = {1925},
  doi = {10.3390/cancers17121925}
}
Kostenlos starten →